Subcutaneous administration of Herceptin Hylecta resulted in non-inferior levels of trastuzumab in the blood (pharmacokinetics) and non-inferior clinical efficacy (pathological complete response ...

Market Implications: This study update could positively influence AstraZeneca’s stock performance and investor sentiment by showcasing the company’s commitment to advancing cancer treatments. As the ...

The study results “highlight how even well-intentioned efforts to save patients’ time may face barriers,” the researchers wrote.

Abstract PD4-07. [8] Sripada et al. Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis.

Sept 13 (Reuters) - Roche Holding AG:Trump-Musk fallout live updates: The split has rattled US politics and markets World · June 6, 2025 A huge public spat on Thursday saw threats fly over ...

Waks: Subcutaneous administration shortened both pharmacy workflow and drug administration time. This can translate into increased capacity to deliver care to more patients -- i.e., improving ...

[4] Tan A, et al. Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: primary analysis of ...

The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer spent getting treatment compared with IV delivery ...

Subcutaneous formulation is administered in 2 to 5 minutes, rather than 30 to 90 minutes with the standard intravenous form1 Subcutaneous formulation offers greater convenience to patients and ...